Sugi Predict

Sugi Predict / Compounds / SCHEMBL1996747

SCHEMBL1996747

SCHEMBL1996747

Cn1cnc2c1CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ NR1H2 P55055 1/20 0.45
▸ P2RX3 P56373 4/20 0.42
▸ PIK3CD O00329 1/20 0.42
▸ GRM5 P41594 1/20 0.42
▸ PDK2 Q15119 3/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ TNKS2 Q9H2K2 1/20 0.41
▸ PARP2 Q9UGN5 1/20 0.41
▸ ADORA1 P30542 1/20 0.40
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ GPR119 Q8TDV5 2/20 0.40
▸ MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29837288 0.91 ESR2 (0.43) ESR2MAPTNR1H2P2RX3PIK3CD
SCHEMBL1992279 0.89 MAPT (0.48) ESR2MAPTNR1H2P2RX3PIK3CD
SCHEMBL30740104 0.87 PIK3CD (0.41) ESR2MAPTNR1H2PIK3CDDDB1
SCHEMBL14659735 0.86 ESR2 (0.46) ESR2MAPTNR1H2P2RX3GRM5
SCHEMBL28948252 0.82 P2RX3 (0.46) ESR2MAPTNR1H2P2RX3PDK2
SCHEMBL31549265 0.81 USP2 (0.44) ESR2MAPTNR1H2P2RX3PIK3CD
SCHEMBL23853006 0.80 HCAR1 (0.48) ESR2MAPTNR1H2PDK2PARP1
SCHEMBL10095078 0.80 PDK2 (0.66) ESR2MAPTNR1H2P2RX3GRM5
SCHEMBL21042235 0.80 P2RX3 (0.44) ESR2MAPTNR1H2P2RX3PDK2
SCHEMBL10095079 0.80 P2RX7 (0.58) MAPTGRM5PDK2DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117347509-A Purity detection method of 1-methyl-1, 4,6, 7-tetrahydro-5H-imidazo [4,5-C ] pyridine-5-carboxylic acid tert-butyl ester 上海凌凯医药科技有限公司 2024-01-05 — — CN claimed
CN-115925702-A Method for purifying imidazo [4,5-C ] pyridine derivative and imidazo [4,5-C ] pyridine derivative 江西凌富生物科技有限公司 2023-04-07 — — CN claimed
CN-117347509-B Purity detection method of 1-methyl-1, 4,6, 7-tetrahydro-5H-imidazo [4,5-C ] pyridine-5-carboxylic acid tert-butyl ester 上海凌凯科技股份有限公司 2026-02-24 — — CN disclosed
CN-117347509-B Purity detection method of 1-methyl-1, 4,6, 7-tetrahydro-5H-imidazo [4,5-C ] pyridine-5-carboxylic acid tert-butyl ester 上海凌凯科技股份有限公司 2026-02-24 — — CN disclosed
US-12552811-B2 Immunosuppressant, and preparation method therefor and use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2026-02-17 — — US disclosed
US-20260035388-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2026-02-05 — — US disclosed
US-12473282-B2 Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2025-11-18 — — US disclosed
US-12466822-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2025-11-11 — — US disclosed
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE INCYTE CORP (US) 2025-10-23 — — US disclosed
CN-115925702-B Purification method of imidazo [4,5-C ] pyridine derivative and imidazo [4,5-C ] pyridine derivative 江西凌富生物科技有限公司 2025-04-25 — — CN disclosed
CN-115605475-B Immunosuppressant, preparation method and application thereof 上海和誉生物医药科技有限公司 2025-03-25 — — CN disclosed
US-20170362253-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-12-21 — — US disclosed
US-20170362253-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-12-21 — — US disclosed
US-20170362253-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-12-21 — — US disclosed
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 — — US disclosed
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 — — US disclosed
EP-3160466-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-05-03 — — EP disclosed
WO-2015200677-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-30 — — WO disclosed
WO-2015200677-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-30 — — WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552811-B2 Immunosuppressant, and preparation method therefor and use thereof CD274, PDCD1, PDCD1LG2 ESR2 3640/4885MAPT 4689/4885NR1H2 197/4885
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE CD274, PDCD1LG2, PDCD1 ESR2 827/4885MAPT 4007/4885NR1H2 495/4885
US-12466822-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS ESR2 1345/4885MAPT 4685/4885NR1H2 278/4885
US-20260035388-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS IL2, IL4, NFATC1 ESR2 1294/4885MAPT 4654/4885NR1H2 1303/4885
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO ESR2 2104/4885MAPT 3071/4885NR1H2 2172/4885
US-12473282-B2 Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof PDCD1, CD274, PDCD1LG2 ESR2 1929/4885MAPT 2758/4885NR1H2 433/4885
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 ESR2 2678/4885MAPT 3461/4885NR1H2 914/4885
US-20170362253-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS ESR2 1345/4885MAPT 4685/4885NR1H2 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.